A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance) Meeting Abstract
| Authors: | Ruppert, A. S.; Byrd, J. C.; Heerema, N. A.; Smith, M. R.; Godwin, J. E.; Couban, S.; Fehniger, T. A.; Thirman, M.; Halvorson, A. E.; Tallman, M. S.; Appelbaum, F. R.; Stone, R. M.; Robinson, S.; Chang, J. E.; Mandrekar, S. J.; Larson, R. A. |
| Abstract Title: | A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance) |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 392s |
| Language: | English |
| ACCESSION: | WOS:000411931708172 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.7503 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 7503 -- Source: Wos |
